Research ArticleClinical Investigations
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette and Hans-Jürgen Wester
Journal of Nuclear Medicine July 2016, 57 (7) 1006-1013; DOI: https://doi.org/10.2967/jnumed.115.168443
Richard P. Baum
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Harshad R. Kulkarni
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Christiane Schuchardt
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Aviral Singh
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Martina Wirtz
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
Stefan Wiessalla
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Margret Schottelius
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
Dirk Mueller
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Ingo Klette
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Hans-Jürgen Wester
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette, Hans-Jürgen Wester
Journal of Nuclear Medicine Jul 2016, 57 (7) 1006-1013; DOI: 10.2967/jnumed.115.168443
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette, Hans-Jürgen Wester
Journal of Nuclear Medicine Jul 2016, 57 (7) 1006-1013; DOI: 10.2967/jnumed.115.168443
Jump to section
Related Articles
Cited By...
- Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation
- Prediction of Response to 177Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC
- Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
- Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
- First Clinical Results for PSMA-Targeted {alpha}-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
- Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
- 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
- JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
- Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
- A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
- Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
- Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- PSMA Ligands for PET Imaging of Prostate Cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
- From NETTER to PETTER: PSMA-Targeted Radioligand Therapy
- Targeted {alpha}-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
- Nuclear Medicine in Cancer Theranostics: Beyond the Target
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer